Prostaglandin E2 Mediated Bone Remodeling Mechanisms

Prostaglandin E₂ (PGE₂) serves as a central lipid mediator in the dynamic balance between bone formation and resorption. Synthesised predominantly by cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1) in osteoblasts and stromal cells, PGE₂ acts in an autocrine and paracrine manner to regulate osteoclast differentiation and osteoblast function. Engagement of PGE₂ with its G-protein-coupled receptors, notably EP2 and EP4, elevates intracellular cAMP levels, triggering downstream effectors such as protein kinase A and exchange protein directly activated by cAMP (Epac). Through EP4-cAMP-Epac signalling, PGE₂ promotes osteoblast early differentiation, matrix production and mineralisation. Conversely, PGE₂ facilitates osteoclastogenesis by upregulating receptor activator of nuclear factor-κB ligand (RANKL) expression and matrix metalloproteinases in osteoblasts, and by modulating inflammatory inputs via toll-like receptor pathways. The net outcome of PGE₂ signalling depends on the cellular context, receptor expression profile and local concentration gradients, making it both a potential therapeutic target for inflammatory bone loss and a candidate for anabolic strategies in osteoporosis.

Research from Nature Portfolio

Studies have demonstrated that bacterial components such as lipoteichoic acid from Gram-positive pathogens provoke alveolar bone loss by inducing COX-2 and mPGES-1 expression in osteoblasts, increasing local PGE₂ production and driving osteoclast differentiation. Ex vivo organ cultures and in vivo periodontitis models confirm that pharmacological inhibition of PGE₂ synthesis attenuates bone resorption. Complementary work on human bone marrow stromal cells reveals that PGE₂ impairs matrix mineralisation via an Epac-dependent cAMP pathway rather than protein kinase A, altering expression of RUNX2, alkaline phosphatase and osteocalcin. Pharmacological blockade of Epac restores mineral deposition and gene expression, underlining the importance of distinct cAMP effectors in PGE₂-mediated bone remodelling.

Prostaglandin E2 Mediated Bone Remodeling Mechanisms publication trend

The graph below shows the total number of articles in prostaglandin e2 mediated bone remodeling mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoblast: Bone-forming cell responsible for synthesis of collagenous matrix and regulation of mineral deposition.

Osteoclast: Multinucleated cell specialised in bone resorption through acidification and proteolytic enzyme release.

RANKL: Receptor activator of nuclear factor-κB ligand; key osteoblast-derived cytokine that drives osteoclast differentiation.

COX-2: Inducible cyclooxygenase enzyme that converts arachidonic acid into prostaglandin H₂, precursor of PGE₂.

mPGES-1: Microsomal prostaglandin E synthase-1; enzyme that catalyses the final step of PGE₂ biosynthesis downstream of COX-2.

EP2 and EP4 receptors: G-protein-coupled PGE₂ receptors that elevate intracellular cAMP, modulating bone cell activity.

Epac: Exchange protein directly activated by cAMP; a cAMP effector that influences cytoskeletal dynamics and gene transcription in bone cells.

References

1. FXR Activation Accelerates Early Phase of Osteoblast Differentiation Through COX-2-PGE2-EP4 Axis in BMP-2-Induced Mouse Mesenchymal Stem Cells. Molecules (2024).
2. Roles of Toll-like Receptor Signaling in Inflammatory Bone Resorption. Biology (2024).
3. Gram-positive bacteria cell wall-derived lipoteichoic acid induces inflammatory alveolar bone loss through prostaglandin E production in osteoblasts. Scientific Reports (2021).
4. Prostaglandin E2 inhibits matrix mineralization by human bone marrow stromal cell-derived osteoblasts via Epac-dependent cAMP signaling. Scientific Reports (2017).
5. Prostate cancer expressing membrane-bound TGF-α induces bone formation mediated by the autocrine effect of prostaglandin E2 in osteoblasts. Biochemical and Biophysical Research Communications (2022).